<DOC>
	<DOCNO>NCT00907738</DOCNO>
	<brief_summary>This study evaluate safety tolerability continue vorinostat ( MK-0683 ) dose cancer patient previously enrol one five base study ( MK-0683-001 , MK-0683-006 , MK-0683-008 , MK-0683-012 , MK-0683-013 ) show benefit receiving drug .</brief_summary>
	<brief_title>A Continuation Clinical Trial Oral Vorinostat ( MK-0683 ) Advanced Cancers ( MK-0683-007 )</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Patient participate one five vorinostat base protocol , show tumor progression study , tolerate study drug Patient withdraw base protocol Patient agree practice effective birth control study Patient receive standard and/or investigational anticancer therapy Patient condition disease would interfere compliance pose addition risk administer study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>